Month: May 2024

Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1) is one subtype among AML with recurrent genetic abnormalities, characterized by the translocation between chromosome 8q22 and chromosome 21q22. This translocation leads to the fusion of the RUNX1 gene on 8q22 with the RUNX1T1 gene on 21q22, forming the RUNX1-RUNX1T1 fusion gene. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing towards better clinical outcomes for patients with hematologic diseases and blood tumors. In this congress, the team led by Yi Luo/Yibo Wu from The First Affiliated Hospital of Zhejiang University School of Medicine in China presented a clinical study, sharing the treatment status and prognosis of AML with t(8;21)(q22;q22.1). This journal is honored to invite Dr. Yibo Wu to share the research findings and their clinical significance with colleagues.

The 2024 CSCO Guideline Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hope Science Clinical Oncology Research Foundation, took place in Jinan on April 26-27. At the event, Professor Jun Guo from Peking University Cancer Hospital was interviewed by "Oncology Frontier." He discussed significant updates in the new editions of the CSCO guidelines for urothelial carcinoma and melanoma, shared insights into the unique features of the CSCO guidelines, and provided an overview of the current and future states of anti-cancer drug development in China.

As time passes and seasons flow, we always embark on new journeys and endeavors through repeated reviews and outlooks. The annual review of the Northern Breast Cancer Salon and the discussion on the 2024 CSCO BC Guidelines update were held from January 5-6, 2024, in Beijing. "Oncology Frontier" specially interviewed Professor Rui Ge from East Hospital affiliated with Fudan University to reflect on the progress in breast cancer treatment i

The 2024 update of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Colorectal Cancer has been released. The new edition incorporates the latest evidence-based medical developments, adds new biomarkers for colorectal cancer, enriches clinical treatment strategy options, and adjusts the recommendation levels for various treatment protocols. Oncology Frontier interviewed Professor Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine, one of the guideline's authors, to discuss the key updates and their clinical significance.

Transurethral resection of bladder tumor (TURBt) is the primary treatment for non-muscle-invasive bladder cancer (NMIBC), but the postoperative tumor recurrence rate remains high, posing a significant clinical challenge. To prevent tumor recurrence, different intravesical therapies are administered post-TURBt based on the patient's recurrence risk level. At the 2024 39th Annual European Association of Urology (EAU24) Congress, several studies focused on postoperative intravesical therapy strategies for NMIBC. Professor Fufu Zheng from The First Affiliated Hospital of Sun Yat-sen University provided a detailed analysis of these studies, exploring precise and individualized treatment strategies for NMIBC.

The 39th Annual European Association of Urology (EAU24) Congress took place from April 5-8, 2024, in Paris, France, focusing on global urological oncology hotspots and the forefront of Chinese urological research. At the event, "Oncology Frontier" invited Professor Wei Zhai from Renji Hospital, affiliated with Shanghai Jiao Tong University School o,(f Medicine, to share his insights and the latest developments in urological oncology research.